Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 3, 2007, Pages 406-407

  Oxelmark, Lena ^a,b,c,d   Hillerås, Pernilla ^b,d   Dignass, Axel ^e   Mössner, Joachim ^f   Schreiber, Stefan ^g   Kruis, Wolfgang ^h   Löfberg, Robert ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c IBD Unit   (Sweden)

^d SOPHIAHEMMET UNIVERSITY COLLEGE   (Sweden)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h Department of Internal Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOMODULATING AGENT; MESALAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; FEMALE; GRANULOCYTE; HUMAN; LEUKAPHERESIS; LEUKOCYTE; MALE; MONOCYTE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; LEUKAPHERESIS; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 33847190245     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600881060     Document Type: Article

References (5)

1. Irvine EJ, Farrokhyar F, Swarbrick ET. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001;Suppl 36:2-15.
2. Kolios G, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. Hepato-gastroenterology 1998;45:1601-9.
3. Saniabadi AR, Hanai H, Suzuki Y, Ohomori T, Sawada K, Yoshimura H, et al. Adacolumn for selective leukocyte apheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;
4. Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005;11:7001-6.
5. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.